CD19 and lymphoma: The preserved functionality of CAR-T cells in presence of emapalumab was confirmed also in vivo, in a lymphoma animal model, in the presence of high doses of emapalumab, administered with a schedule of 3 infusions, 4-day apart, concomitant with the onset of toxicity or concurrent with the infusion of CAR.CD19-T cells.